10-K/A: Aldeyra Therapeutics Files Amendment to 10-K to Correct Accounting Firm Consent

Aldeyra Therapeutics files an amendment to its original Form 10-K to correct an administrative error in the consent of its independent registered public accounting firm.

Summary

• Aldeyra Therapeutics, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment corrects an administrative error in Exhibit 23.1, the Consent of Independent Registered Public Accounting Firm.
• The original filing date of the Form 10-K was February 28, 2025.
• The amendment does not revise the company's financial statements or any other disclosure in the original Form 10-K.
• New certifications by the company's principal executive officer and principal financial officer are included as exhibits.
• The company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code as no financial statements are being filed with this Amendment.
• As of February 26, 2025, there were 59,708,654 shares of the registrant's Common Stock issued and outstanding.
• As of June 30, 2024, the aggregate market value of the registrant's Common Stock held by non-affiliates was approximately $191,737,565.

Sentiment

Score: 7

Explanation: The document is a routine amendment to correct a minor error. It doesn't indicate any significant positive or negative developments for the company, hence a neutral to slightly positive sentiment.

Positives

• The company promptly addressed and corrected an administrative error in its filing.
• The correction did not require revisions to the financial statements or other disclosures, suggesting a contained issue.

Management Comments

• Todd C. Brady, M.D., Ph.D., certifies that the report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
• Michael Alfieri certifies that the report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Industry Context

This is a standard regulatory filing update, specifically an amendment to correct a minor error. It doesn't significantly relate to broader industry trends but highlights the importance of accuracy in regulatory submissions within the pharmaceutical industry.

Comparison to Industry Standards

• Correcting errors in SEC filings is a common practice across the industry.
• The nature of the error (administrative in the accounting firm's consent) is relatively minor compared to restatements due to accounting irregularities, which can have significant market impact.
• Comparable companies also routinely file amendments to their 10-K reports for various reasons, ranging from clarifying disclosures to correcting errors.

Stakeholder Impact

• The correction of the error ensures accurate information for shareholders and potential investors.
• The amendment has minimal impact on employees, customers, suppliers, and creditors.

Key Dates

Keywords

Form 10-K/A, amendment, financial reporting, Aldeyra Therapeutics, consent of independent registered public accounting firm, BDO USA, P.C., Sarbanes-Oxley Act, certification